No argument with that. The completed CLBP phase 3 trial has already guided some precision, as we agree. And it's more than possible RWE could add further refinement to identifying likely responders when data accumulates after approval. Another non-NGS example which gives us great joy is the huge advantage patients with elevated CRP enjoy from Revascor. No genetic analysis required there, just a simple blood test.
No argument with that. The completed CLBP phase 3 trial has...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.005(0.34%) |
Mkt cap ! $1.649B | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.49 | $1.44 | $1.970M | 1.354M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 3177 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 18057 | 6 |
View Market Depth
| Last trade - 12.45pm 21/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |